Cargando…

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a monoclonal antibody directed against CD52 that depletes T and B lymphocytes. OBJECTIVE: To evaluate the treatment effect of alemtuzumab on low-contrast vision in relapsing–remitting multiple sclerosis (RRMS) patients. METHODS: This was a pre-defined exploratory analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graves, Jennifer, Galetta, Steven L, Palmer, Jeffrey, Margolin, David H, Rizzo, Marco, Bilbruck, John, Balcer, Laura J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807733/ https://www.ncbi.nlm.nih.gov/pubmed/23459567 http://dx.doi.org/10.1177/1352458513475722

Ejemplares similares

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
por: Guarnera, Cristina, et al.
Publicado: (2017)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis
por: Arroyo, Rafael, et al.
Publicado: (2019)

Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Alemtuzumab‐induced petechiae and epistaxis in a patient with relapsing–remitting multiple sclerosis: A case report
por: Mahmoudi, Farhad, et al.
Publicado: (2023)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE
por: Perumal, Jai, et al.
Publicado: (2019)

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing–Remitting Multiple Sclerosis: STRIVE Data Analysis
por: Perumal, Jai, et al.
Publicado: (2023)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients()
por: Graziano, Elliot, et al.
Publicado: (2015)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study
por: Perumal, Jai, et al.
Publicado: (2022)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study
por: Perumal, Jai, et al.
Publicado: (2023)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
por: Okai, Annette F., et al.
Publicado: (2019)

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis
por: Koudriavtseva, Tatiana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d6c85ucd7kpjskqm82n23jiig4